India's Central Drugs Standard Control Organisation (CDSCO) has granted Syntellix the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market. In one fell swoop, this increases global market access and the amount of potential patients who can be treated with the company's MAGNEZIX^® implants by an additional 1.38 billion to now 3.8 billion people.

The healthcare system of India, which according to unanimous forecasts will soon become the world's most populous country, and the country's market for medical devices are growing rapidly. Public healthcare spending is expected to increase by 2.5 times already until 2025. According to the Ministry of Health and Family Welfare, meanwhile more than 62 percent of India's in-patient treatments take place in private facilities. India's private healthcare sector alone can thus treat up to ten times as many people as Germany in total.

-> Go to press release